説明

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 10億 2021-2027, 年間複合成長率で成長する (CAGR) の 8.6% 予測期間中, データ分析会社StrategyHelixによると. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

レポートは、期間の最新の市場規模データを提供します。 2017-2020 そして次のように予測します 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, テクノロジー, age, analysis target, と地域. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, 血液学, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. テクノロジー別, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, その他. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., アジレント・テクノロジー株式会社, BGIグループ, Centogene AG, Eurofins Scientific SE, 株式会社イルミナ, Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

このレポートは、この業界で活動する企業や組織にとって非常に貴重なリソースです。. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, 政策立案者, アカデミック, とアナリスト.

レポートの範囲

Disease: 心血管系, central nervous system, endocrine and metabolic, 血液学, immune and inflammation, rare cancers, and other diseases
テクノロジー: polymerase chain reaction (PCR), next-generation sequencing, microarrays, その他
Age: children, and adult
領域: 北米, アジア太平洋地域, ヨーロッパ, および世界のその他の地域 (行)
Analysis target: multiple genes, whole exome, single genes, and whole genome
考慮された年数: このレポートはその期間をカバーしています 2017 に 2027

関係者にとっての主なメリット

Get a comprehensive picture of the global rare disease diagnostics market
地域のデータと分析に基づいて地域戦略と戦略的優先事項を特定する
成長セクターと投資トレンドを正確に特定する
Understand what the future of the global rare disease diagnostics market looks like
競争環境と機会の窓を特定する

目次

1. 市場の定義
2. 研究方法
3. 市場データ & 見通し
3.1 市場価格
3.2 市場価値の予測
4. Rare Disease Diagnostics Market by Disease
4.1 心臓血管
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 血液学
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 その他
6. Rare Disease Diagnostics Market by Age
6.1 子供たち
6.2 アダルト
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 北米
8.2 アジア太平洋地域
8.3 ヨーロッパ
8.4 世界のその他の地域 (行)
9. 会社概要
9.1 3billion Inc.
9.2 アジレント・テクノロジー株式会社.
9.3 BGIグループ
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 イルミナ株式会社.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, 株式会社.
9.10 Quest Diagnostics Incorporated
10. 付録
10.1 StrategyHelix について
10.2 免責事項